Literature DB >> 14614891

Role of surgery and radiation therapy in the management of gestational trophoblastic disease.

John T Soper1.   

Abstract

Although sensitive human chorionic gonadotrophin (hCG) assays and advances in chemotherapy have assumed primary importance in the management of gestational trophoblastic disease (GTD), surgery and radiation therapy remain important in the overall management of patients. Management of molar pregnancies consists of surgical evacuation and subsequent monitoring. Hysterectomy may decrease the risk of post-molar trophoblastic disease. When incorporated into the primary management of malignant GTD, hysterectomy decreases chemotherapy requirements for patients with low-risk disease. Surgical intervention is frequently required to control complications of disease or as therapy to stabilize patients during chemotherapy. Salvage hysterectomy or other extirpative procedures may be integrated into the management of patients with chemorefractory disease. Interventional radiographical techniques are useful adjuncts to control haemorrhage from vaginal or pelvic metastases. Radiation therapy may also be combined with chemotherapy for the management of patients with brain metastases or, rarely, isolated metastases at other sites.

Entities:  

Mesh:

Year:  2003        PMID: 14614891     DOI: 10.1016/s1521-6934(03)00091-9

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  9 in total

Review 1.  The role of surgery and radiation therapy in the management of gestational trophoblastic disease.

Authors:  Rabbie K Hanna; John T Soper
Journal:  Oncologist       Date:  2010-05-23

2.  Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12.

Authors:  Yusuke Kobayashi; Takatsune Shimizu; Hideaki Naoe; Arisa Ueki; Joe Ishizawa; Tatsuyuki Chiyoda; Nobuyuki Onishi; Eiji Sugihara; Osamu Nagano; Kouji Banno; Shinji Kuninaka; Daisuke Aoki; Hideyuki Saya
Journal:  Am J Pathol       Date:  2011-07-23       Impact factor: 4.307

3.  Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.

Authors:  Raymond J Osborne; Virginia L Filiaci; Julian C Schink; Robert S Mannel; Kian Behbakht; James S Hoffman; Nick M Spirtos; John K Chan; John A Tidy; David S Miller
Journal:  Obstet Gynecol       Date:  2016-09       Impact factor: 7.661

4.  Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015).

Authors:  C Tempfer; L-C Horn; S Ackermann; M W Beckmann; R Dittrich; J Einenkel; A Günthert; H Haase; J Kratzsch; M C Kreissl; S Polterauer; A D Ebert; K T M Schneider; H G Strauss; F Thiel
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

5.  A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.

Authors:  T Powles; P M Savage; J Stebbing; D Short; A Young; M Bower; C Pappin; P Schmid; M J Seckl
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

6.  A pilot randomized controlled clinical trial of second uterine curettage versus usual care to determine the effect of re-curettage on patients' need for chemotherapy among women with low risk, nonmetastatic gestational trophoblastic neoplasm in Urmia, Iran.

Authors:  Haleh Ayatollahi; Zahra Yekta; Elnaz Afsari
Journal:  Int J Womens Health       Date:  2017-09-21

7.  Role of surgical therapy in the management of gestational trophoblastic neoplasia.

Authors:  Kyung Jin Eoh; Young Shin Chung; Ga Won Yim; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  Obstet Gynecol Sci       Date:  2015-07-16

8.  Perimenopausal invasive hyadatidiform mole treated by total abdominal hysterectomy followed by chemotherapy.

Authors:  Ayaka Nakashima; Ai Miyoshi; Takashi Miyatake; Ogita Kazuhide; Yokoi Takeshi
Journal:  J Surg Case Rep       Date:  2016-09-20

9.  Thoracoscopic Surgery to Treat Lung Metastases from Refractory Choriocarcinoma.

Authors:  Luo Zhao; Yingzhi Qin; Dongjie Ma; Li Li; Zhijun Han; Shanqing Li; Hongsheng Liu
Journal:  Cancer Manag Res       Date:  2020-05-25       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.